SOLU-CORTEF (hydrocortisone sodium succinate) by Pfizer is clinical pharmacology glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. First approved in 1955.
Drug data last refreshed Just now · AI intelligence enriched 34m ago
SOLU-CORTEF is a water-soluble injectable glucocorticoid (hydrocortisone sodium succinate) approved in 1955 for rapid delivery of high-dose hydrocortisone. It functions as a broad-spectrum anti-inflammatory and immunosuppressant agent, enabling immediate intravenous administration where rapid systemic glucocorticoid effect is required. The drug treats adrenocortical deficiency, acute inflammatory conditions, and emergency shock states across multiple organ systems.
Product is in late maturity with minimal Part D claims, signaling a stable but contracted brand team with focus on maintenance rather than expansion.
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on SOLU-CORTEF at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on SOLU-CORTEF offers limited growth trajectory and zero currently linked job openings, reflecting its legacy status and mature market position. Career opportunities focus on institutional relationships, regulatory compliance, and cost-containment strategies rather than market expansion or innovation.